^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Small Intestinal Carcinoma

    Apply
    A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers (NCT04708470)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    10/05/2021
    Primary completion :
    12/01/2025
    Completion :
    12/01/2026
    PD-L1 • CD4
    |
    PD-L1 negative
    |
    Jingzhuda (entinostat) • bintrafusp alfa (M7824) • PDS01ADC
    Testing Obeticholic Acid for Familial Adenomatous Polyposis (NCT05223036)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    01/19/2023
    Primary completion :
    01/31/2026
    Completion :
    02/21/2026
    APC
    |
    APC mutation
    Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (SWOG S1609) (NCT02834013)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    01/30/2017
    Primary completion :
    05/01/2026
    Completion :
    05/01/2026
    CD4
    |
    PD-L1 overexpression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • MK-1088
    Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas (NCT05565417)
    Phase 1/2
    Immunitas Therapeutics
    Recruiting
    Last update posted :
    05/03/2024
    Initiation :
    11/28/2022
    Primary completion :
    04/01/2025
    Completion :
    04/01/2025
    KRAS • BRAF • ALK • PIK3CA • MET • MSI
    |
    BRAF V600E • KRAS mutation • HR positive • MSI-H/dMMR • HER-2 overexpression • PIK3CA mutation
    |
    Fruzaqla (fruquintinib) • IMT-009
    Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders (NCT04729322)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    05/02/2024
    Initiation :
    02/22/2021
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    MSI • MLH1 • MSH6 • MSH2 • CEACAM5
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab)
    Quebec Pancreas Cancer Study (QPCS) (NCT04104230)
    Phase N/A
    George Zogopoulos
    Recruiting
    Last update posted :
    04/17/2024
    Initiation :
    03/12/2012
    Primary completion :
    01/01/2025
    Completion :
    01/01/2025
    BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1
    |
    ATM mutation • STK11 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation
    Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors (NCI-2018-01399) (NCT03108131)
    Phase 2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    04/05/2024
    Initiation :
    04/07/2017
    Primary completion :
    04/02/2024
    Completion :
    04/02/2024
    PD-L1
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • Cotellic (cobimetinib)
    Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy (NCT02381561)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    03/07/2024
    Initiation :
    02/01/2016
    Primary completion :
    11/08/2018
    Completion :
    03/05/2025
    CD4
    |
    ropidoxuridine (IPdR)
    Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma (NCT01815749)
    Phase 1
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    01/04/2024
    Initiation :
    10/08/2013
    Primary completion :
    01/09/2018
    Completion :
    09/27/2024
    EGFR • CD34
    Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery (ZEBRA) (NCT02949219)
    Phase 2
    Academic and Community Cancer Research United
    Active, not recruiting
    Last update posted :
    12/28/2023
    Initiation :
    03/24/2017
    Primary completion :
    01/31/2019
    Completion :
    03/31/2024
    PD-L1 • MSI
    |
    Keytruda (pembrolizumab)
    Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers (ARM-GI) (NCT04221893)
    Phase N/A
    University of California, San Francisco
    Recruiting
    Last update posted :
    11/17/2023
    Initiation :
    08/07/2020
    Primary completion :
    12/31/2024
    Completion :
    11/30/2026
    MSI • PD-1
    Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers (NCT04491955)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    11/14/2023
    Initiation :
    09/22/2020
    Primary completion :
    10/25/2022
    Completion :
    01/31/2026
    CEACAM5 • CD4
    |
    bintrafusp alfa (M7824) • Anktiva (nogapendekin alfa inbakicept-pmln) • PDS01ADC • Panvac-VF (falimarev/inalimarev)